These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 10582025)

  • 1. [The morphological characteristics and immunohemostatic mechanisms of the development of diabetic retinopathy].
    Balashova LM
    Vestn Oftalmol; 1999; 115(5):45-8. PubMed ID: 10582025
    [No Abstract]   [Full Text] [Related]  

  • 2. [Contribution of selected cellular adhesion molecules and proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy].
    Adamiec J; Oficjalska-Młyńczak J
    Przegl Lek; 2007; 64(6):389-92. PubMed ID: 18159844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of diabetic retinopathy.
    Oberman AE
    Trans Pac Coast Otoophthalmol Soc Annu Meet; 1974; 55():167-77. PubMed ID: 4619231
    [No Abstract]   [Full Text] [Related]  

  • 4. [Content of immunoglobulins in the vitreous body and of antibodies to vitreous body antigens in the blood serum of patients with proliferative diabetic retinopathy].
    Glinchuk IaI; Lazarenko LF; Emets VI; Deev LA; Arapova OIu
    Vestn Oftalmol; 1987; 103(2):46-9. PubMed ID: 3603952
    [No Abstract]   [Full Text] [Related]  

  • 5. [Morphologic studies of the vitreous body in diabetic retinopathies].
    Agafonov VA; Barabash NS
    Vestn Oftalmol; 1986; 102(5):61-5. PubMed ID: 3787951
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in general hemostasis in patients with diabetic retinopathy].
    Evgrafov VIu; Markova OA; Grishin VL; Efimov VS
    Vestn Oftalmol; 2004; 120(3):29-31. PubMed ID: 15216770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy.
    Demircan N; Safran BG; Soylu M; Ozcan AA; Sizmaz S
    Eye (Lond); 2006 Dec; 20(12):1366-9. PubMed ID: 16284605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could diabetic retinopathy be an autoimmune disease?
    Kastelan S; Zjacić-Rotkvić V; Kastelan Z
    Med Hypotheses; 2007; 68(5):1016-8. PubMed ID: 17125935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema.
    Gandorfer A; Haritoglou C; Kampik A
    Am J Ophthalmol; 2006 Jan; 141(1):234-5; author reply 235. PubMed ID: 16387030
    [No Abstract]   [Full Text] [Related]  

  • 10. Intrasurgical plasmin enzyme in diabetic macular edema.
    Gandorfer A; Kampik A
    Am J Ophthalmol; 2005 May; 139(5):949; author reply 949-50. PubMed ID: 15860323
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ocular changes in diabetes mellitus (without diabetic retinopathy)].
    Davidescu FL
    Oftalmologia; 2004; 48(4):13-7. PubMed ID: 15782757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrasurgical plasmin enzyme in diabetic macular edema.
    Azzolini C; D'Angelo A; Maestranzi G; Codenotti M; Della Valle P; Prati M; Brancato R
    Am J Ophthalmol; 2004 Oct; 138(4):560-6. PubMed ID: 15488781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of proliferative diabetic retinopathy.
    Gündüz K; Bakri SJ
    Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunological factors and diabetic retinopathy].
    Wahl P
    Ber Zusammenkunft Dtsch Ophthalmol Ges; 1970; 70():148-52. PubMed ID: 5537460
    [No Abstract]   [Full Text] [Related]  

  • 15. Development and progression of diabetic retinopathy in patients with Type 1 diabetes who are positive for GAD autoantibody.
    Mimura T; Funatsu H; Uchigata Y; Kitano S; Shimizu E; Noma H; Amano S; Araie M; Iwamoto Y; Hori S
    Diabet Med; 2004 Jun; 21(6):559-62. PubMed ID: 15154939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precortical vitreous pockets and proliferative retinopathy.
    Sebag J
    Ophthalmology; 1993 Nov; 100(11):1599-600. PubMed ID: 8233376
    [No Abstract]   [Full Text] [Related]  

  • 17. [Disorders in the immune regulation and hemostasis as factors triggering the proliferative retinopathy in diabetes mellitus].
    Zaĭtseva NS; Balashova LM; Teplinskaia LE; Grishin VL; Gankovskaia LV
    Vestn Ross Akad Med Nauk; 2003; (5):28-32. PubMed ID: 12800486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impaired antiendotoxin immunity in patients with diabetic retinopathy and type 2 diabetes mellitus].
    Zhaboedov GD; Kopaenko AI
    Vestn Oftalmol; 2005; 121(6):29-31. PubMed ID: 16405060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of metabolic immunosuppression in the development of diabetic involvement of the fundus oculi].
    Kashintseva LT; Degtiarenko TV; Saldan IR; Bakuleva NV
    Oftalmol Zh; 1983; 38(3):162-6. PubMed ID: 6604892
    [No Abstract]   [Full Text] [Related]  

  • 20. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
    Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
    Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.